HALOZYME THERAPEUTICS, INC. Available-for-sale Securities, Current
HALOZYME THERAPEUTICS, INC. (HALO) had Available-for-sale Securities, Current of $263.36 million as of 2020-03-31, per its 10-Q filed 2020-05-11.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesCurrent · last filed 2020-05-11
- 2020-03-31: Available-for-sale Securities, Current $263.36M.
- 2019-12-31: Available-for-sale Securities, Current $301.08M.
- 2019-09-30: Available-for-sale Securities, Current $178.80M.
- 2019-06-30: Available-for-sale Securities, Current $220.42M.
| Period end | Available-for-sale Securities, Current | Available-for-sale Securities, Current as first filed |
|---|---|---|
| 2020-03-31 | $263.36M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $301.08M 10-Q · filed 2020-05-11 | |
| 2019-09-30 | $178.80M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $220.42M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $268.12M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $296.59M 10-K · filed 2020-02-24 | |
| 2018-09-30 | $309.35M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $343.72M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $335.68M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $300.47M 10-K · filed 2019-02-21 | |
| 2017-09-30 | $152.53M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $182.79M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $133.80M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $138.22M 10-K · filed 2018-02-20 | |
| 2016-09-30 | $159.84M 10-Q · filed 2016-11-07 | |
| 2016-06-30 | $168.76M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $169.54M 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $65.05M 10-K · filed 2017-02-28 | |
| 2015-09-30 | $52.20M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $72.95M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $84.21M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $74.23M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $88.09M 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $91.51M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $87.92M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $44.15M 10-K · filed 2015-03-02 | $44.15M 10-K · filed 2014-02-28 |
| 2013-09-30 | $47.82M 10-Q · filed 2013-11-08 | |
| 2013-06-30 | $48.08M 10-Q · filed 2013-08-07 | |
| 2012-12-31 | $0.00 10-K · filed 2014-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |